Asset Acquisition and License Agreements	3 Months Ended
Mar. 31, 2019
Research And Development [Abstract]
Asset Acquisition and License Agreements	7. Asset Acquisition and License Agreements SRX Cardio, LLC In December 2015, we entered into an option agreement with SRX Cardio to explore a novel approach to develop a drug in the field of hypercholesterolemia. This agreement provided us an option to enter into an exclusive license agreement as well as responsibility to lead and fund the development effort during the option period. We made an upfront payment of $0.5 million. In September 2016, we exercised our right to enter into an exclusive license agreement. We determined that SRX Cardio is and continues to be a variable interest entity and that we hold a variable interest in SRX Cardio’s intellectual property assets and the related potential future product candidates these assets may produce. Due to the absence of other significant development programs at SRX Cardio, we concluded that the variable interest was in the entity as a whole. Given the stage of development, we concluded that SRX Cardio is not considered a business as they lack the processes required to generate outputs. Further, because we control those activities most significant to SRX Cardio, we are considered to be the primary beneficiary of SRX Cardio. Accordingly, SRX Cardio is subject to consolidation and we have consolidated the financial statements of SRX Cardio. As of March 31, 2019, we have not provided financial or other support to SRX Cardio that was not previously contracted or required. We recorded SRX Cardio’s $29,000 and $30,000 of cash as restricted cash as of March 31, 2019 and December 31, 2018, respectively, because (a) we do not have any interest in or control over SRX Cardio's cash and (b) the agreement does not provide for these assets to be used for the development of the intellectual property assets developed pursuant to this agreement. We recorded $60,000 as net income attributable to noncontrolling interest (SRX Cardio) for the three months ended March 31, 2019 on our condensed consolidated statements of operations, reflecting the change in fair value of our contingent future payments liability to SRX Cardio as of March 31, 2019.

Asset Acquisition and License Agreements

3 Months Ended

Mar. 31, 2019

Asset Acquisition and License Agreements

7. Asset Acquisition and License Agreements

SRX Cardio, LLC

In December 2015, we entered into an option agreement with SRX Cardio to explore a novel approach to develop a drug in the field of hypercholesterolemia. This agreement provided us an option to enter into an exclusive license agreement as well as responsibility to lead and fund the development effort during the option period. We made an upfront payment of $0.5 million.

In September 2016, we exercised our right to enter into an exclusive license agreement. We determined that SRX Cardio is and continues to be a variable interest entity and that we hold a variable interest in SRX Cardio’s intellectual property assets and the related potential future product candidates these assets may produce. Due to the absence of other significant development programs at SRX Cardio, we concluded that the variable interest was in the entity as a whole. Given the stage of development, we concluded that SRX Cardio is not considered a business as they lack the processes required to generate outputs. Further, because we control those activities most significant to SRX Cardio, we are considered to be the primary beneficiary of SRX Cardio. Accordingly, SRX Cardio is subject to consolidation and we have consolidated the financial statements of SRX Cardio.

As of March 31, 2019, we have not provided financial or other support to SRX Cardio that was not previously contracted or required. We recorded SRX Cardio’s $29,000 and $30,000 of cash as restricted cash as of March 31, 2019 and December 31, 2018, respectively, because (a) we do not have any interest in or control over SRX Cardio's cash and (b) the agreement does not provide for these assets to be used for the development of the intellectual property assets developed pursuant to this agreement. We recorded $60,000 as net income attributable to noncontrolling interest (SRX Cardio) for the three months ended March 31, 2019 on our condensed consolidated statements of operations, reflecting the change in fair value of our contingent future payments liability to SRX Cardio as of March 31, 2019.